Physician profile
Jonathan S Staub
NPI 1831290279
$1,665.74
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,300 · 2020: $366.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.18 | 2019-2020 | |
| Novo Nordisk INC | $219.93 | 2019-2020 | |
| Amgen INC. | $168.18 | 2019-2020 | |
| Pfizer INC. | $133.29 | 2019-2020 | |
| Glaxosmithkline, LLC. | $121.56 | 2019-2020 | |
| Amarin Pharma, INC. | $101.39 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.60 | 2019-2020 | |
| Lilly USA, LLC | $86.88 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $72.65 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $64.55 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $38.46 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $38.22 | 2019-2020 | |
| Dynavax Technologies Corporation | $35.61 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $33.80 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $26.64 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $26.40 | 2019 | |
| Ironwood Pharmaceuticals, INC | $25.72 | 2019 | |
| Genzyme Corporation | $17.97 | 2019 | |
| Grifols USA, LLC | $15.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.38 | 2019 | |
| Radius Health, INC. | $13.04 | 2019 | |
| Biodelivery Sciences International, INC. | $13.01 | 2020 | |
| Genentech USA, INC. | $11.99 | 2019 | |
| Hikma Pharmaceuticals USA | $11.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.13 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Staub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.